| abstract |
(57) Abstract The novel compounds of formula (1) are useful for treating diseases responsive to the opener of high conductance calcium activated potassium channels. Wherein "Het" represents one of the selected heterocyclic groups; Z is independently selected at each occurrence from O or S; R a , R b , R c are each independently hydrogen, halogen, OH, CF 3 , NO 2 , or Wherein R c is not hydrogen; when R a and R b are hydrogen, R c is imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl and pyridine-2 A heterocyclic group selected from the group consisting of -yl; R d and R e are each independently selected from hydrogen, halogen, CF 3 , NO 2 , or imidazol-1-yl; m , N and p are each independently selected from 0 or 1; and R f and R g are each independently hydrogen; C 1-4 alkyl; or R f and R g are N- together with the nitrogen atom to which they are attached. It is a heterocyclic group selected from the group consisting of methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine, and imidazolinone. |